Net sales for the year ended December 31, 2025, were $5,636,000, a decrease from $7,739,000 in 2024. Gross profit margin remained healthy at approximately 55%. Operating loss improved to ($3,854,000) in 2025 from ($4,105,000) in 2024. Net loss improved to $(3,749,000), or ($0.19) per basic and diluted share, compared to $(4,477,000), or ($0.22) per share, in 2024. International revenue grew to approximately 29% of total revenue in 2025, up from 21% in the prior year. Total operating expenses were reduced by approximately 10% in 2025. Sales backlog grew during 2025 to approximately $1.8 million. Cash and cash equivalents were $88,000 as of December 31, 2025, with working capital of $1.0 million. The accumulated deficit as of December 31, 2025, was $58.1 million. The company completed a $535,000 convertible note financing in 2025 and entered into an Equity Line of Credit (ELOC) for up to $20,000,000 in November 2025, with a first draw of $94,130 in February 2026. The total opportunity book for integration projects is $16 million, and the entire SteraMist iHP opportunity book is currently at $20 million.